Preeclampsia (PE) is a serious pregnancy complication characterized by new-onset hypertension and signs of maternal organ dysfunction, often accompanied by placental abnormalities and systemic endothelial dysfunction. PE is associated with adverse maternal and perinatal outcomes and confers an increased long-term risk of cardiovascular and metabolic disease for both mother and offspring. This prospective observational cohort study aims to establish a longitudinal pregnancy and birth cohort of women diagnosed with preeclampsia. Pregnant women with a clinical diagnosis of PE according to current obstetric guidelines will be recruited at their initial presentation either in the in- or outpatient clinic or in the delivery ward, respectively and followed through late pregnancy, delivery, and early postpartum. Participants will undergo study visits during pregnancy, sample collection at delivery, and a postpartum visit 8-12 weeks after birth. Clinical data, physical measurements, questionnaire-based information, and biological samples will be collected from mothers and infants to enable comprehensive phenotyping of pregnancies complicated by preeclampsia. Data and biosamples from this cohort will be used for descriptive and hypothesis-driven analyses and may be compared with data from an existing longitudinal cohort of healthy pregnancies to support interpretation of preeclampsia-associated biological and clinical changes.
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Maternal metabolic and cardiometabolic phenotype: hemodynamic assessments 1
Timeframe: From study enrollment after PE diagnosis through 8-12 weeks postpartum
Maternal metabolic and cardiometabolic phenotype: Adiposity
Timeframe: From study enrollment after PE diagnosis through 8-12 weeks postpartum
Maternal metabolic and cardiometabolic phenotype: hemodynamic assessments 2
Timeframe: from study enrollment after PE diagnosis through 8-12 weeks postpartum
Maternal metabolic and cardiometabolic phenotype: Cytokine Profile
Timeframe: From study enrollment after PE diagnosis through 8-12 weeks postpartum
Maternal metabolic and cardiometabolic phenotype: Lipid profile
Timeframe: From study enrollment after PE diagnosis through 8-12 weeks postpartum
Maternal metabolic and cardiometabolic phenotype: hemodynamic assessments 3
Timeframe: From study enrollment after PE diagnosis through 8-12 weeks postpartum
Maternal metabolic and cardiometabolic phenotype: Echocardiography
Timeframe: From study enrollment after PE diagnosis through 8-12 weeks postpartum
Infant outcomes: hemodynamic assessment
Timeframe: At birth and at 8-12 weeks postpartum
Infant outcomes: body composition
Timeframe: At birth and at 8-12 weeks postpartum
Infant outcomes: hemodynamic assessment
Timeframe: At birth and at 8-12 weeks postpartum